Skip to main content

Advertisement

SpringerLink
Log in

Cell cycle and no end

  • Review Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Our knowledge about the molecular circuits regulating the duplication of the genetic material and the subsequent division of a cell into two daughter cells has exploded over the last decade. Aberrations in the regulation of the cell cycle belong to the hallmarks of malignant transformation, leading, in turn, to the development of tumours. After introducing the basics of eukaryotic cell-cycle regulation and describing the four phases of the cell cycle (namely, G1, S, G2 and M) in more detail, alterations of key components of the cell-cycle machinery in human malignancies and their functional consequences are presented. Principally, deregulation of the cell cycle can be caused by unrestricted activity of cell-cycle promoting factors (many oncogenes fall into this class) or by inactivation of inhibitory factors (many tumour suppressor genes belong to this class). Both types of deregulation have been described in human tumours and are discussed in detail. Perspectives concerning the translation of this knowledge into daily routine practice and future applications are discussed at the end. The molecular mechanisms of actual cell division (sister chromatid segregation and cytokinesis) are mentioned only briefly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177–2196

    Article  CAS  PubMed  Google Scholar 

  2. Aggerholm A, Guldberg P, Hokland M, Hokland P (1999) Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res 59:436–441

    CAS  PubMed  Google Scholar 

  3. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54

    Article  CAS  PubMed  Google Scholar 

  4. Bartek J, Lukas J, Bartkova J (1999) Perspective: defects in cell cycle control and cancer. J Pathol 187:95–99

    Article  CAS  PubMed  Google Scholar 

  5. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528–2531

    CAS  PubMed  Google Scholar 

  6. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052–3065

    CAS  PubMed  Google Scholar 

  7. Blow JJ, Hodgson B (2002) Replication licensing—defining the proliferative state? Trends Cell Biol 12:72–78

    Article  CAS  PubMed  Google Scholar 

  8. Boldt DH (2002) p21(CIP1/WAF1/SDI1) hypermethylation: an exciting new lead in ALL biology. Blood 99:2283

    Article  CAS  PubMed  Google Scholar 

  9. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PT (2002) Aurora B kinase exists in a complex with survivin and INCENP, and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell 13:3064–3077

    Article  CAS  PubMed  Google Scholar 

  10. Borg A, Ferno M, Peterson C (2003) Predicting the future of breast cancer. Nat Med 9:16–18

    Article  CAS  PubMed  Google Scholar 

  11. Carnero A (2002) Targeting the cell cycle for cancer therapy. Br J Cancer 87:129–133

    Article  CAS  PubMed  Google Scholar 

  12. Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB (1999) Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18:4047–4054

    Article  CAS  PubMed  Google Scholar 

  13. Classon M, Harlow E (2002) The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2:910–917

    Article  CAS  PubMed  Google Scholar 

  14. Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J (1999) Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 112:S40–S52

    CAS  PubMed  Google Scholar 

  15. Douglas RM, Haddad GG (2003) Genetic models in applied physiology: invited review: effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest. J Appl Physiol 94:2068–2083

    CAS  PubMed  Google Scholar 

  16. Elledge SJ (1996) Cell cycle checkpoints: preventing an identity crisis. Science 274:1664–1672

    CAS  PubMed  Google Scholar 

  17. Endl E, Gerdes J (2000) The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257:231–237

    CAS  PubMed  Google Scholar 

  18. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O’Brien S, Garcia-Manero G, Manshouri T, Albitar M (2002) Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 16:1045–1052

    Article  CAS  PubMed  Google Scholar 

  19. Falini B, Mason DY (2002) Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 99:409–426

    Article  CAS  PubMed  Google Scholar 

  20. Furnari B, Rhind N, Russell P (1997) Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 277:1495–1497

    CAS  PubMed  Google Scholar 

  21. Gali-Muhtasib H, Bakkar N (2002) Modulating cell cycle: current applications and prospects for future drug development. Curr Cancer Drug Targets 2:309–336

    CAS  PubMed  Google Scholar 

  22. Gerlach C, Golding M, Larue L, Alison MR, Gerdes J (1997) Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. Lab Invest 77:697–698

    CAS  PubMed  Google Scholar 

  23. Hahn WC, Weinberg RA (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331–341

    Article  CAS  PubMed  Google Scholar 

  24. Hall M, Peters G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67–108

    CAS  PubMed  Google Scholar 

  25. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY (2003) Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 83:241–247

    Article  PubMed  Google Scholar 

  26. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    CAS  PubMed  Google Scholar 

  27. Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257–261

    CAS  PubMed  Google Scholar 

  28. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816

    CAS  PubMed  Google Scholar 

  29. Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246:629–634

    CAS  PubMed  Google Scholar 

  30. Heppner GH, Miller FR (1998) The cellular basis of tumor progression. Int Rev Cytol 177:1–56

    CAS  PubMed  Google Scholar 

  31. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525–4530

    CAS  PubMed  Google Scholar 

  32. Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, O’Connell BC, Mateyak MK, Tam W, Kohlhuber F, Dang CV, Sedivy JM, Eick D, Vogelstein B, Kinzler KW (2000) Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A 97:2229–2234

    Article  CAS  PubMed  Google Scholar 

  33. Johnson DG, Walker CL (1999) Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39:295–312

    Article  CAS  PubMed  Google Scholar 

  34. Johnston JM, Carroll WL (1992) c-myc hypermutation in Burkitt’s lymphoma. Leuk Lymphoma 8:431–439

    CAS  PubMed  Google Scholar 

  35. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819

    PubMed  Google Scholar 

  36. Katayama H, Brinkley WR, Sen S (2003) The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451–464

    Article  PubMed  Google Scholar 

  37. Kato H, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Takita J, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Asao T, Kuwano H (2003) A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 84:24–30

    Article  CAS  PubMed  Google Scholar 

  38. Kawabe T, Suganuma M, Ando T, Kimura M, Hori H, Okamoto T (2002) Cdc25C interacts with PCNA at G2/M transition. Oncogene 21:1717–1726

    Article  CAS  PubMed  Google Scholar 

  39. Kelly TJ, Brown GW (2000) Regulation of chromosome replication. Annu Rev Biochem 69:829–880

    CAS  PubMed  Google Scholar 

  40. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575

    Article  CAS  PubMed  Google Scholar 

  41. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646

    Article  CAS  PubMed  Google Scholar 

  42. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel Doeberitz M (2002) p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 26:1389–1399

    Article  PubMed  Google Scholar 

  43. Kreipe H, Parwaresch R (1993) A closer look at the cell cycle. Virchows Arch 422:341–343

    CAS  Google Scholar 

  44. Laronga C, Yang HY, Neal C, Lee MH (2000) Association of the cyclin-dependent kinases and 14–3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275:23106–23112

    Article  CAS  PubMed  Google Scholar 

  45. Lee MH, Yang HY (2001) Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 58:1907–1922

    CAS  PubMed  Google Scholar 

  46. Lee MH, Yang HY (2003) Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 22:435–449

    Article  CAS  PubMed  Google Scholar 

  47. Lee MH, Reynisdottir I, Massague J (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639–649

    PubMed  Google Scholar 

  48. Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29[Suppl 1]:41–48

    Google Scholar 

  49. Lillo C, Velasco A, Jimeno D, Cid E, Lara JM, Aijon J (2002) The glial design of a teleost optic nerve head supporting continuous growth. J Histochem Cytochem 50:1289–1302

    CAS  PubMed  Google Scholar 

  50. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313–323

    CAS  PubMed  Google Scholar 

  51. Lundberg AS, Weinberg RA (1999) Control of the cell cycle and apoptosis. Eur J Cancer 35:1886–1894

    Article  CAS  PubMed  Google Scholar 

  52. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222–231

    Article  CAS  PubMed  Google Scholar 

  53. Mandell JW (2003) Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 163:1687–1698

    CAS  PubMed  Google Scholar 

  54. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D (1995) A novel p16INK4A transcript. Cancer Res 55:2995–2997

    CAS  PubMed  Google Scholar 

  55. McCoy ML, Mueller CR, Roskelley CD (2003) The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod Biol Endocrinol 1:72

    Google Scholar 

  56. Melino G, De Laurenzi V, Vousden KH (2002) p73: friend or foe in tumorigenesis. Nat Rev Cancer 2:605–615

    Article  CAS  PubMed  Google Scholar 

  57. Molinari M (2000) Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 33:261–274

    CAS  PubMed  Google Scholar 

  58. Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261–291

    Google Scholar 

  59. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2:21–32

    CAS  PubMed  Google Scholar 

  60. Nishitani H, Lygerou Z (2002) Control of DNA replication licensing in a cell cycle. Genes Cells 7:523–534

    Article  CAS  PubMed  Google Scholar 

  61. Nouman GS, Anderson JJ, Lunec J, Angus B (2003) The role of the tumour suppressor p33 ING1b in human neoplasia. J Clin Pathol 56:491–496

    Article  CAS  PubMed  Google Scholar 

  62. Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K (2002) Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 8:817–822

    CAS  PubMed  Google Scholar 

  63. Nurse P (2000) A long twentieth century of the cell cycle and beyond. Cell 100:71–78

    CAS  PubMed  Google Scholar 

  64. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA (2002) Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36:617–656

    Article  CAS  PubMed  Google Scholar 

  65. Oya M, Schulz WA (2000) Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer 83:626–631

    Article  CAS  PubMed  Google Scholar 

  66. Pan ZQ, Reardon JT, Li L, Flores-Rozas H, Legerski R, Sancar A, Hurwitz J (1995) Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J Biol Chem 270:22008–22016

    Article  CAS  PubMed  Google Scholar 

  67. Park MT, Lee SJ (2003) Cell cycle and cancer. J Biochem Mol Biol 36:60–65

    CAS  PubMed  Google Scholar 

  68. Paulovich AG, Toczyski DP, Hartwell LH (1997) When checkpoints fail. Cell 88:315–321

    CAS  PubMed  Google Scholar 

  69. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66

    CAS  PubMed  Google Scholar 

  70. Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, Richter KH, Walker C, Beach D, Sherr CJ, Serrano M (1995) Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11:635–645

    CAS  PubMed  Google Scholar 

  71. Ravitz MJ, Wenner CE (1997) Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res 71:165–207

    CAS  PubMed  Google Scholar 

  72. Richardson P (2003) Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 29[Suppl 1]:33–39

    Google Scholar 

  73. Rocco JW, Sidransky D (2001) p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264:42–55

    Article  CAS  PubMed  Google Scholar 

  74. Roman-Gomez J, Castillejo JA, Jimenez A, Gonzalez MG, Moreno F, Rodriguez Mdel C, Barrios M, Maldonado J, Torres A (2002) 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99:2291–2296

    Article  CAS  PubMed  Google Scholar 

  75. Ross JS (1996) DNA ploidy and cell cycle analysis in cancer diagnosis and prognosis. Oncology (Huntingt) 10:867–882, 887; discussion 887–890

    Google Scholar 

  76. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497–1501

    CAS  PubMed  Google Scholar 

  77. Sandal T (2002) Molecular aspects of the mammalian cell cycle and cancer. Oncologist 7:73–81

    CAS  PubMed  Google Scholar 

  78. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K (2003) C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 5:R30–R36

    Article  CAS  PubMed  Google Scholar 

  79. Scholey JM, Brust-Mascher I, Mogilner A (2003) Cell division. Nature 422:746–752

    Article  CAS  PubMed  Google Scholar 

  80. Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322

    CAS  PubMed  Google Scholar 

  81. Scholzen T, Endl E, Wohlenberg C, van der Sar S, Cowell IG, Gerdes J, Singh PB (2002) The Ki-67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher-order chromatin structure. J Pathol 196:135–144

    CAS  PubMed  Google Scholar 

  82. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, Sauter G (2003) Cyclin E overexpression and amplification in human tumours. J Pathol 200:375–382

    Article  CAS  PubMed  Google Scholar 

  83. Sen S, Zhou H, White RA (1997) A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14:2195–2200

    Article  CAS  PubMed  Google Scholar 

  84. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320–1329

    Google Scholar 

  85. Seo YH, Joo YE, Choi SK, Rew JS, Park CS, Kim SJ (2003) Prognostic significance of p21 and p53 expression in gastric cancer. Korean J Intern Med 18:98–103

    CAS  PubMed  Google Scholar 

  86. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707

    CAS  PubMed  Google Scholar 

  87. Sharpless E, Chin L (2003) The INK4a/ARF locus and melanoma. Oncogene 22:3092–3098

    Article  CAS  PubMed  Google Scholar 

  88. Shen L, Kondo Y, Issa JP, Garcia-Manero G (2002) Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. Blood 100:3432–3434

    Article  CAS  Google Scholar 

  89. Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677

    CAS  PubMed  Google Scholar 

  90. Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60:3689–3695

    CAS  PubMed  Google Scholar 

  91. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512

    CAS  PubMed  Google Scholar 

  92. Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3:155–168

    Article  CAS  PubMed  Google Scholar 

  93. Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297–300

    CAS  PubMed  Google Scholar 

  94. Steeg PS, Zhou Q (1998) Cyclins and breast cancer. Breast Cancer Res Treat 52:17–28

    Article  CAS  PubMed  Google Scholar 

  95. Stewart ZA, Westfall MD, Pietenpol JA (2003) Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 24:139–145

    Article  CAS  PubMed  Google Scholar 

  96. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A (1995) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988–2994

    CAS  PubMed  Google Scholar 

  97. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y (1999) Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 59:2041–2044

    CAS  PubMed  Google Scholar 

  98. Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, Lehmann U (2003) Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 17:910–918

    Article  CAS  PubMed  Google Scholar 

  99. Toyoshima H, Hunter T (1994) p27, a novel inhibitor of G1 cyclin–CDK protein kinase activity, is related to p21. Cell 78:67–74

    CAS  PubMed  Google Scholar 

  100. van Bokhoven H, McKeon F (2002) Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. Trends Mol Med 8:133–139

    Article  PubMed  Google Scholar 

  101. Venkitaraman AR (1999) Breast cancer genes and DNA repair. Science 286:1100–1102

    Article  CAS  PubMed  Google Scholar 

  102. Vermeulen K, Berneman ZN, Van Bockstaele DR (2003) Cell cycle and apoptosis. Cell Prolif 36:165–175

    CAS  PubMed  Google Scholar 

  103. Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36:131–149

    CAS  PubMed  Google Scholar 

  104. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284

    CAS  PubMed  Google Scholar 

  105. Wong IH, Ng MH, Huang DP, Lee JC (2000) Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95:1942–1949

    CAS  PubMed  Google Scholar 

  106. Wood RD, Shivji MK (1997) Which DNA polymerases are used for DNA-repair in eukaryotes? Carcinogenesis 18:605–610

    Article  CAS  PubMed  Google Scholar 

  107. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704

    CAS  PubMed  Google Scholar 

  108. Yam CH, Fung TK, Poon RY (2002) Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59:1317–1326

    Article  Google Scholar 

  109. Yang A, Kaghad M, Caput D, McKeon F (2002) On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 18:90–95

    Article  PubMed  Google Scholar 

  110. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189–193

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to apologise for any omissions in the reference list due to strict space limitations. The authors would like to thank Nisar P. Malek for advice and Florian Länger for critically reading the manuscript and two anonymous reviewers for critical comments. Research grant support: Deutsche Krebshilfe, 10–1842-Le I. Deutsche Forschungsgemeinschaft, SFB265. Deutsche Forschungsgemeinschaft, DFG Fe 516/1–2.

Author information

Authors and Affiliations

  1. Institute of Pathology, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 , Hannover, Germany

    Mathewos Tessema, Ulrich Lehmann & Hans Kreipe

Authors
  1. Mathewos Tessema
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans Kreipe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans Kreipe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tessema, M., Lehmann, U. & Kreipe, H. Cell cycle and no end. Virchows Arch 444, 313–323 (2004). https://doi.org/10.1007/s00428-003-0971-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-003-0971-3

Keywords

Search

Navigation